Evidence map›Paper›PMID 41121364›Full record

ArticleBreast cancer research : BCR2025

Morphological analysis of tumor microenvironment in HER2-positive breast cancer: predicting response to neoadjuvant chemotherapy on histopathological images.

Wensheng Cui, Ming Fan, Lihua Li

Abstract read
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wensheng CuiSchool of Computer Science and Technology, Hangzhou Dianzi University, Hangzhou, 310018, China.
Ming FanInstitute of Biomedical Engineering and Instrumentation, Hangzhou Dianzi University, Hangzhou, 310018, China. ming.fan@hdu.edu.cn.
Lihua LiSchool of Computer Science and Technology, Hangzhou Dianzi University, Hangzhou, 310018, China. lilh@hdu.edu.cn.

Funding

National Natural Science Foundation of China 62271178National Natural Science Foundation of China U21A20521Natural Science Foundation of Zhejiang Province of China LR23F010002
6 · The paper itself

Abstract

backgroundHER2-positive breast cancer (HER2 + BC) is clinically distinct from other subtypes, such as triple-negative or hormone receptor–positive breast cancers, due to its unique tumor microenvironment (TME) and its heterogeneous response to neoadjuvant chemotherapy (NAC). Given the critical role of the TME in treatment outcomes, we investigated whether TME features extracted from histopathological images can predict pathological complete response (pCR) and guide personalized therapy.

methodsWe retrospectively analyzed 147 HER2 + BC patients treated with NAC, including 85 from the Yale Response dataset (training cohort) and 62 from the IMPRESS HER2+ dataset (external validation cohort). Hematoxylin and eosin-stained histopathology images were segmented using VGG-16 and Xception networks to generate tissue segmentation images (TS-images). Based on the TS-images, tumor and stroma regions were segmented. Intratumoral and stromal tumor-infiltrating lymphocytes (iTILs and sTILs, respectively) were extracted from these regions and then combined to form TILs. The morphological features of these regions were quantitatively characterized using connected component analysis. Feature selection was performed by integrating morphological and clinical data via the least absolute shrinkage and selection operator. The selected features were then used to train a multilayer perceptron model, which was validated on the IMPRESS HER2+ dataset.

resultsIn external validation, the model based on sTILs achieved an AUC of 0.873 for pCR prediction, with an F1 score of 0.889, PPV of 0.821, recall of 0.970, and NPV of 0.933. This performance substantially outperformed models trained on stroma (AUC = 0.779), tumor (0.732), iTILs (0.594), and TILs (0.668). Notably, the sTILs-based model maintained high performance (AUC = 0.722) even when trained with 20% of the training cohort. Univariate analyses identified morphological predictors for pCR, including the filled area of significant regions (mean) in sTILs (P value = 0.015).

conclusionMorphological TME features from histopathological images can accurately predict pCR in HER2 + BC, supporting their use in guiding NAC decision-making.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesTumor MicroenvironmentAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansImage Processing, Computer-AssistedLymphocytes, Tumor-InfiltratingNeoadjuvant TherapyPathologic Complete ResponsePrognosisRetrospective StudiesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesBreast cancerDeep learningHistopathological imagesNeoadjuvant chemotherapyTumor microenvironment

Identifiers

PMID41121364
PMCPMC12542099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.